Axsome Therapeutics to Participate in Upcoming Investor Conferences
MWN-AI** Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical leader in treating central nervous system (CNS) disorders, has announced its participation in several noteworthy investor conferences taking place in March 2026. These events include the TD Cowen 46th Annual Health Care Conference in Boston, the Leerink Partners Global Healthcare Conference, and the Citizens Life Sciences Conference, both in Miami Beach. Additionally, Axsome will hold meetings at the UBS Biotech Summit and the 2026 Jefferies Biotech on the Beach Summit.
The company aims to share insights into its innovative neuroscience portfolio, which includes FDA-approved therapies for remarkable conditions such as major depressive disorder, excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea, and migraine. Axsome is committed to advancing the treatment landscape for over 150 million patients in the U.S. facing serious neurological and psychiatric conditions.
Investors and stakeholders may access live webcasts of presentations from the TD Cowen, Leerink, and Citizens conferences on Axsome’s website, with replays available for about 30 days post-event.
While Axsome continues to make strides in its product development, it also reminds investors that certain statements presented may be forward-looking and subject to risks and uncertainties. These risks include the commercial success of existing products like SUNOSI®, AUVELITY®, and SYMBRAVO®, challenges in clinical trials, regulatory approvals, and potential intellectual property issues. Despite these challenges, Axsome Therapeutics remains dedicated to finding solutions to complex brain disorders, and it encourages engagement from the investment community to further their mission. For more information, visit their website or follow along on social media.
MWN-AI** Analysis
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is strategically positioned to make significant advancements in the treatment of central nervous system (CNS) disorders, an area that affects millions. As the company gears up to participate in several investor conferences this March, the upcoming events represent not only a platform for engagement but also an opportunity for investors to assess Axsome’s potential trajectory amid its ongoing developments.
With a robust portfolio that includes FDA-approved treatments for conditions such as major depressive disorder and narcolepsy, Axsome is strategically innovating to fill critical gaps in CNS treatment. The upcoming TD Cowen, Leerink Partners, and Citizens conferences will provide insights into the company’s present operations and future strategies, particularly focusing on the commercial success and market acceptance of its products, including SUNOSI® and AUVELITY®.
Investors should closely monitor these presentations and prepare for potential volatility in AXSM stock prices depending on the information shared. The management is likely to shed light on pivotal issues such as payer coverage expansion and anticipated clinical trial results, particularly with their late-stage development programs. Given that biotechnology stocks can experience rapid fluctuations based on trial outcomes and regulatory approvals, diligent investors might view these conferences as a litmus test for Axsome's near-term stratagem and investor confidence.
However, prospective investors must remain mindful of inherent risks. The forward-looking statements in Axsome's recent press release underscore various uncertainties, including the ability to secure regulatory approvals and the financial implications of ongoing trials. Thus, while participation in the upcoming conferences could energize interest and possibly lead to a surge in stock performance, prudent investors should weigh these prospects against the backdrop of the inherent risks in the biopharma sector before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March:
- TD Cowen 46th Annual Health Care Conference
Fireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA
- Leerink Partners Global Healthcare Conference
Fireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL
- The Citizens Life Sciences Conference
Fireside Chat: Tuesday, March 10, 2026, at 4:00 p.m. ET in Miami Beach, FL
- UBS Biotech Summit Miami – Catalyst for Change
Investor Meetings: Tuesday, March 10, 2026, in Miami Beach, FL
- 2026 Jefferies Biotech on the Beach Summit
Investor Meetings: Wednesday, March 11, 2026, in Miami Beach, FL
Live webcasts of the presentations at the TD Cowen, Leerink, and Citizens conferences can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. Replays of the webcasts will be available for approximately 30 days following each event.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ**
How does Axsome Therapeutics Inc. (AXSM) plan to leverage its participation in the upcoming investor conferences to enhance investor confidence in its CNS treatment portfolio?
What updates can we expect from Axsome Therapeutics Inc. (AXSM) regarding its late-stage development programs during the March investor conferences?
Given the competitive landscape, how does Axsome Therapeutics Inc. (AXSM) differentiate its CNS therapies, particularly those currently in late-stage development?
What key milestones does Axsome Therapeutics Inc. (AXSM) aim to achieve in 2026 that will impact its clinical trials and FDA approval processes for its product candidates?
**MWN-AI FAQ is based on asking OpenAI questions about Axsome Therapeutics Inc. (NASDAQ: AXSM).
NASDAQ: AXSM
AXSM Trading
-1.12% G/L:
$160.475 Last:
154,575 Volume:
$159.80 Open:
